LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Suletud

Sektor Tervishoid

1,130.9 -1.48

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1129.97

Max

1135.51

Põhinäitajad
By Trading Economics
Sissetulek	710M 1.4B
Müük	400M 3.6B
P/E Sektori keskmine	31.03 103.001
Aktsiakasum	11.56
Kasumimarginaal	40.346
Töötajad	13,450
EBITDA	933M 1.8B

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+4.43 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	31. okt 2024

Turustatistika
By TradingEconomics
Turukapital	130B
Eelmine avamishind	1132.38
Eelmine sulgemishind	1130.9

Uudiste sentiment

By Acuity

13%

87%

82 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

N/A / 1199.12 Toetus ja vastupanu

Regeneron Pharmaceuticals Inc Graafik

Seotud uudised

8. juuli 2024, 12:00 UTC

Tulu

Regeneron Expects Earnings Hit After $24 Million R&D Charge

2. mai 2024, 11:02 UTC

Tulu

Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales

2. veebr 2024, 11:59 UTC

Tulu

Regeneron's 4Q Sales Edge Higher, Despite Softening Demand for Covid Products

1. aug 2024, 11:50 UTC

Tulu

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1. aug 2024, 10:37 UTC

Tulu

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1. aug 2024, 10:30 UTC

Tulu

Regeneron Pharma 2Q EPS $12.41 >REGN

1. aug 2024, 10:30 UTC

Tulu

Regeneron Pharma 2Q Net $1.43B >REGN

1. aug 2024, 10:30 UTC

Tulu

Regeneron Pharma 2Q Rev $3.55B >REGN

20. juuni 2024, 20:16 UTC

Peamised uudised

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20. juuni 2024, 18:09 UTC

Peamised uudised

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20. juuni 2024, 11:00 UTC

Peamised uudised

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- WSJ

2. mai 2024, 10:32 UTC

Tulu

Regeneron Pharma Cuts 2024 Capital Spending View to $780M-$880M From $825M-$950M >REGN

2. mai 2024, 10:32 UTC

Tulu

Regeneron Pharma Still Sees 2024 Adjusted Gross Margin 89%-91% >REGN

2. mai 2024, 10:31 UTC

Tulu

Regeneron Pharma Sets New $3 Billion Share-Repurchase Program >REGN

2. mai 2024, 10:30 UTC

Tulu

Regeneron Pharma 1Q Rev $3.15B >REGN

2. mai 2024, 10:30 UTC

Tulu

Regeneron Pharma 1Q Adj EPS $9.55 >REGN

2. mai 2024, 10:30 UTC

Tulu

Regeneron Pharma 1Q EPS $6.27 >REGN

2. mai 2024, 10:30 UTC

Tulu

Regeneron Pharma 1Q Net $722M >REGN

11. apr 2024, 13:47 UTC

Kuumad aktsiad

Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands -- WSJ

5. veebr 2024, 12:00 UTC

Peamised uudised

What a $200 Billion Blockbuster Drug Reveals About Big Pharma's Playbook -- Heard on the Street -- WSJ

2. veebr 2024, 17:05 UTC

Tulu

Regeneron Earnings Beat Forecasts as Sales of Updated Eye Drug Raise Hopes -- Barrons.com

2. veebr 2024, 14:13 UTC

Tulu

The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High -- IBD

2. veebr 2024, 11:36 UTC

Tulu

Regeneron Pharma Sees 2024 Capital Spending $825M-$950M >REGN

2. veebr 2024, 11:36 UTC

Tulu

Regeneron Pharma Sees 2024 Adjusted Gross Margin 89%-91% >REGN

2. veebr 2024, 11:36 UTC

Tulu

Regeneron Pharma Sees 2024 Adjusted R&D Spending $4.3B-$4.5B >REGN

2. veebr 2024, 11:31 UTC

Tulu

Regeneron Pharma: 4Q Dupixent Global Sales, Recorded by Sanofi, Rose 31% to $3.22B >REGN

2. veebr 2024, 11:31 UTC

Tulu

Regeneron Pharma 4Q U.S. Eylea HD, Eylea Sales $1.46B >REGN

2. veebr 2024, 11:30 UTC

Tulu

Regeneron Pharma 4Q EPS $10.19 >REGN

2. veebr 2024, 11:30 UTC

Tulu

Regeneron Pharma 4Q Rev $3.43B >REGN

2. veebr 2024, 09:37 UTC

Tulu

These Stocks Are Moving the Most Today: Meta, Amazon, Apple, Intel, Deckers, Skechers, Clorox, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Regeneron Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

4.43% tõus

12 kuu keskmine prognoos

Keskmine 1,181.61 USD 4.43%

Kõrge 1,292 USD

Madal 870 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Regeneron Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

19 ratings

Osta

Hoia

Müü

Põhineb 19 analüütiku instrumendi Regeneron Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 1199.12Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

82 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.